TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 368,300 shares, a growth of 355.3% from the January 15th total of 80,900 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 55.7% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of TransCode Therapeutics in a report on Thursday, February 6th.

TransCode Therapeutics Stock Down 0.5 %

Shares of RNAZ stock traded down $0.05 during trading hours on Wednesday, reaching $10.78. 104,066 shares of the stock traded hands, compared to its average volume of 3,518,095. TransCode Therapeutics has a 1-year low of $2.66 and a 1-year high of $66.33. The business has a fifty day moving average price of $5.78 and a 200 day moving average price of $283.07.

Hedge Funds Weigh In On TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its holdings in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the period. Sheets Smith Wealth Management owned about 0.29% of TransCode Therapeutics worth $29,000 as of its most recent SEC filing.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.